ITP vs. FNAIT in Pregnancy: What's the Difference?
At a Glance
Maternal ITP and FNAIT are fundamentally different conditions. ITP is an autoimmune disorder where your body attacks its own platelets. FNAIT is an alloimmune condition where your immune system attacks the baby's platelets. Having a history of ITP does not cause your baby to develop FNAIT.
If you have a history of Immune Thrombocytopenia (ITP), it is completely understandable to worry about how it might affect your baby’s platelets. The most important thing to know is that ITP and FNAIT are entirely different conditions [1][2]. Having ITP does not mean your baby will develop Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) during your pregnancy [2][3].
While both conditions involve the immune system and platelets, they work in fundamentally different ways. ITP is an autoimmune condition, meaning your body attacks your own platelets [2][4]. FNAIT is an alloimmune condition, meaning the mother’s immune system is perfectly healthy but reacts to the baby’s foreign platelets as if they were an invader, similar to Rh disease [1].
Autoimmune vs. Alloimmune: What’s the Difference?
To understand why these conditions are different, it helps to look at exactly what the immune system is targeting.
- In Maternal ITP (Autoimmune): Your immune system makes “autoantibodies” that get confused and target your own platelets for destruction [2]. Because of this, mothers with active ITP usually have low platelet counts themselves (though if your ITP is well-managed or in remission, your counts might be normal) [2]. These antibodies can sometimes cross the placenta and temporarily lower the baby’s platelets, but this is typically mild and resolves on its own [2][5].
- In FNAIT (Alloimmune): Your immune system is functioning normally and is not attacking your own platelets. Instead, it recognizes specific proteins (antigens) on the baby’s platelets—which they inherited from their father—as foreign [1]. The mother produces “alloantibodies” against these foreign proteins. Crucially, a mother carrying a baby with FNAIT will usually have completely normal platelet counts, because her own platelets are not being attacked [6].
How They Affect the Baby
While both ITP and FNAIT can result in a baby being born with low platelets (neonatal thrombocytopenia), the severity is very different [1].
- Neonatal Thrombocytopenia from ITP: If maternal ITP antibodies cross the placenta, the baby’s platelets might drop. However, severe bleeding complications in the newborn are rare [2]. Doctors will closely monitor both your platelet count during pregnancy and your baby’s platelet count during and after delivery (typically starting with a blood test right after birth) to ensure they do not need treatment [7].
- FNAIT: Because the mother’s antibodies are specifically targeting the baby’s unique platelet proteins, FNAIT tends to cause a much more severe drop in the baby’s platelets [1]. It is a leading cause of severe newborn thrombocytopenia and carries a higher risk of serious bleeding complications, such as intracranial hemorrhage (bleeding in the brain) [6][8]. Because this dangerous bleeding can happen in utero (before the baby is even born) [6], doctors will often treat the mother during pregnancy (such as with IVIG) to protect the baby [9][10].
Summary of Key Differences
| Feature | Maternal ITP | FNAIT |
|---|---|---|
| Immune System Problem | Autoimmune (attacks self) [2] | Alloimmune (attacks foreign proteins) [1] |
| Mother’s Platelet Count | Typically low if active [2] | Typically normal [6] |
| Target of Antibodies | Mother’s own platelets [2] | Baby’s platelets (inherited from father) [1] |
| Risk of Severe Bleeding in Baby | Low [2] | High (e.g., intracranial hemorrhage) [6] |
| Does ITP cause this? | N/A | No [2][3] |
If you have a history of ITP, your obstetrician or a maternal-fetal medicine specialist will monitor your pregnancy closely to ensure you and your baby remain safe [7][4]. However, you do not need to worry that your ITP is turning into or causing FNAIT. They remain two separate conditions with two distinct management paths.
Common questions in this guide
Does having ITP mean my baby will develop FNAIT?
How does maternal ITP affect my baby's platelets?
Will I have low platelets if my baby has FNAIT?
How will my baby's platelets be checked after birth if I have ITP?
Why is FNAIT considered more dangerous for the baby than maternal ITP?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Monitoring platelets
How closely would my platelet count be monitored during pregnancy?
Effects on the baby
Could antibodies from my ITP cross the placenta and lower my baby's platelets?
ITP versus FNAIT
Could my ITP lead to FNAIT in my baby, or are they separate conditions?
Related questions
Get notified when new evidence is published on Fetal and neonatal alloimmune thrombocytopenia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (10)
- 1
Fetal and neonatal alloimmune thrombocytopenia.
Zdravic D, Yougbare I, Vadasz B, et al.
Seminars in fetal & neonatal medicine 2016; (21(1)):19-27.
PMID: 26810319 - 2
Immune Thrombocytopenic Purpura and Maternal and Neonatal Outcomes During Pregnancy: A Systematic Review and Meta-Analysis.
Zhang H, Shi L, Shang H, Yang H
American journal of reproductive immunology (New York, N.Y. : 1989) 2024; (92(5)):e70008 doi:10.1111/aji.70008.
PMID: 39498982 - 3
Characterization of glycoprotein IIb/IIIa-specific alloantibodies induced by cross-strain platelet immunization in mice.
Bougie DW, Sutton J, Aster RH
Transfusion 2021; (61(4)):1278-1285 doi:10.1111/trf.16275.
PMID: 33483962 - 4
Neonatal Outcome of Pregnancies Complicated with Idiopathic Thrombocytopenia.
Zahid S, Asmat R, Ehsan N, et al.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2020; (30(7)):745-748 doi:10.29271/jcpsp.2020.07.745.
PMID: 32811607 - 5
Neonates born to mothers with immune thrombocytopenic purpura: a single-center experience of 20 years.
Bayhan T, Tavil B, Korkmaz A, et al.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2016; (27(1)):19-23 doi:10.1097/MBC.0000000000000378.
PMID: 26258676 - 6
Imaging and management of fetuses and neonates with alloimmune thrombocytopenia.
Kovanlikaya A, Tiwari P, Bussel JB
Pediatric blood & cancer 2017; (64(12)) doi:10.1002/pbc.26690.
PMID: 28675682 - 7
Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy.
Sun D, Shehata N, Ye XY, et al.
Blood 2016; (128(10)):1329-35 doi:10.1182/blood-2016-04-710285.
PMID: 27402971 - 8
Maternal anti-platelet β3 integrins impair angiogenesis and cause intracranial hemorrhage.
Yougbaré I, Lang S, Yang H, et al.
The Journal of clinical investigation 2015; (125(4)):1545-56.
PMID: 25774504 - 9
Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach.
Lieberman L, Greinacher A, Murphy MF, et al.
British journal of haematology 2019; (185(3)):549-562 doi:10.1111/bjh.15813.
PMID: 30828796 - 10
Epidemiology and management of fetal and neonatal alloimmune thrombocytopenia.
de Vos TW, Winkelhorst D, de Haas M, et al.
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2020; (59(1)):102704 doi:10.1016/j.transci.2019.102704.
PMID: 31974030
This page provides educational information about the differences between ITP and FNAIT. It does not replace professional medical advice. Always consult your maternal-fetal medicine specialist or obstetrician about your specific pregnancy risks and platelet monitoring plan.